Biospecimen Procurement for Genitourinary Malignancies Branch Immunotherapy Protocols
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Hodgkin Disease
- Leukemia-Lymphoma, Adult T-Cell
- Lymphoma Non-Hodgkin
- Multiple Myeloma
- Non -Small Cell Lung Cancer
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Background: -Immunotherapy is a promising approach to the treatment of cancer. GMB investigators are studying immunotherapy for the treatment of diverse malignant and premalignant conditions. These studies require the collection of biospecimens for research purposes. Objectives: To collect and bank ...
Background: -Immunotherapy is a promising approach to the treatment of cancer. GMB investigators are studying immunotherapy for the treatment of diverse malignant and premalignant conditions. These studies require the collection of biospecimens for research purposes. Objectives: To collect and bank blood, apheresis products, tumor, body fluids, and other biospecimens from patients with cancer or a premalignant disease or at risk of cancer from an immunodeficiency. To collect and bank biospecimens as directed by companion GMB immunotherapy clinical trial protocols. To conduct nucleic acid, protein, and immunological and biological research studies on samples collected. Eligibility: -Patients must be 18 years of age or older with a diagnosis of cancer or a premalignant condition or an immunodeficiency that increases the risk of being diagnosed with a cancer or premalignant condition. Design: Up to 500 subjects will be enrolled. Patients will undergo sampling of blood, apheresis products, tumor, effusions, ascites, urine, bone marrow, serum, plasma, skin, mucosa, or other tissues for banking and laboratory studies. No investigational or experimental therapy will be given as part of this protocol.
Tracking Information
- NCT #
- NCT02682667
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Scott M Norberg, D.O. National Cancer Institute (NCI)